Supplementary file 1_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.docx

類似資料

• Supplementary file 2_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.docx
  著者:: Xiaohu Jin (9618675)
  出版事項: (2025)
• Data Sheet 1_Anti-HER2/neu TCR-T Cells in Action: linking transcriptional signatures, secretomics, and In Vivo tumor suppression.docx
  著者:: Saleh Alrhmoun (19193851)
  出版事項: (2025)
• Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan
  著者:: Kazuhito Suzuki (22688384)
  出版事項: (2025)
• Line plots of performance metrics across TFIDF conditions.
  著者:: Stefan Saverimuttu (20882325)
  出版事項: (2025)
• Supplementary Data 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
  著者:: Gregory L. Beatty (15087193)
  出版事項: (2025)